Now available to order in Europe, the Metabolon Verus™ Metabolomics Profiling Kit delivers results in just five days, with human and rodent blood sample types and proven reproducibility across eight independent laboratories
MORRISVILLE, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Metabolon, Inc., the global leader in metabolomics solutions advancing life sciences research, diagnostics, therapeutics, and precision medicine, today announced that the Metabolon Verus™ Metabolomics Profiling Kit is now available to order in Europe in addition to the US, with expanded validation beyond the previously supported human plasma, serum, and urine matrices to now include rodent plasma and serum.
The expanded sample-matrix validation broadens the kit's utility for both human and non-human research applications. Additional validation against reference datasets demonstrated accuracy and precision in metabolite identification and quantification across the newly supported matrices, providing researchers with greater confidence in metabolomics results generated from different sample types. Together with the kit's established workflow, these capabilities enable laboratories worldwide to investigate biochemical changes across a wider range of experimental designs, biological models, and sample-collection protocols.
"The real value of the Metabolon Verus Kit is the ability to scale metabolomics without necessarily expanding the team. For core facilities like ours, analyzing hundreds of samples efficiently while maintaining high-quality, consistent data and minimizing batch effects is critical. The standardized workflow and streamlined data processing help reduce turnaround time, allowing us to spend less time processing data and more time interpreting the biological findings. Ultimately, this enables us to support larger studies and deliver meaningful insights to our collaborators faster," said Hardik Shah, Metabolomics Platform Director at the University of Chicago Comprehensive Cancer Center.
The Metabolon Verus™ Metabolomics Profiling Kit delivers results in five days via integrated sample preparation, automated metabolite annotation, and access to Metabolon's Integrated Bioinformatics Platform. By combining a standardized laboratory workflow with Metabolon's data-processing infrastructure and scientific expertise, the kit enables researchers to establish and scale metabolomics capabilities within their own laboratories while maintaining access to the resources needed for consistent, reproducible results. A reference library covering more than 1,500 metabolites across 100 biochemical sub-pathways supports diverse research applications, while built-in quality controls help ensure data consistency and simplify downstream analysis.
European availability builds on Metabolon's Early Access Program, which involved 10 laboratories across five countries. Participants applied the kit to research spanning microbiome biology, stem cell transplantation, and neurological and pulmonary conditions. Their feedback helped refine training, implementation, and customer support for broader international adoption. An international ring trial across eight independent laboratories further demonstrated the kit's reproducibility, identifying an average of 735 metabolites across 90 biochemical pathways per human plasma sample set, with 89% metabolite overlap between sites. Metabolite abundances correlated strongly with expert-curated reference datasets (median coefficient of 0.91), while fed-versus-fasted biological findings remained consistent across laboratories.
"European availability of the Metabolon Verus Metabolomics Profiling Kit, together with expanded support for rodent plasma and serum, represents an important step in making high-quality metabolomics more accessible to researchers worldwide," said Ro Hastie, CEO of Metabolon. "By broadening the range of validated sample types while giving laboratories greater control over study execution, we are enabling researchers to apply metabolomics across a range of human and non-human studies. These advancements make it easier for organizations to bring metabolomics in-house and incorporate biochemical insights into their broader multiomics research programs."
With US and now European availability, expanded sample-matrix support, and demonstrated interlaboratory reproducibility, the kit makes high-quality, in-house metabolomics more accessible for preclinical, translational, and multiomics research.
The Metabolon Verus™ Metabolomics Profiling Kit is now available to order in Europe in addition to the US. To learn more or place an order, visit www.metabolon.com/metabolon-verus-metabolomics-profiling-kit/.
About Metabolomics
Metabolomics, the large-scale study of all small molecules in a biological system, is the only omics technology that provides a complete, current-state functional readout of that system. Metabolomics helps researchers see beyond individual genetic variation, capturing the combined impact of genetic and external factors, such as drugs, diet, lifestyle, and the microbiome, on human health. By measuring thousands of discrete chemical signals that form biological pathways in the body, metabolomics can reveal important biomarkers, enabling a better understanding of a drug's mechanism of action, pharmacodynamics, and safety profile, as well as individual responses to therapy. Metabolomics anchors multiomic discovery in biological function, helping organizations reduce uncertainty and make more confident scientific and business decisions.
About Metabolon
Metabolon, Inc. is the global leader in metabolomics, with a mission to deliver biochemical data and insights that expand and accelerate the impact of life sciences research and complement other 'omics' technologies. With more than 25 years of metabolomics leadership, 15,000+ projects, 4,000+ publications, and ISO 9001:2015, CLIA, and CAP certifications, Metabolon has developed industry-leading scientific, technological, and bioinformatics techniques. Metabolon's Global Discovery Panel is powered by the world's largest proprietary metabolomics reference library, while Metabolon's expanding portfolio of solutions enables researchers to access Metabolon-standard metabolomics through both centralized services and in-house workflows. The Metabolon Verus™ Metabolomics Profiling Kit extends Metabolon's validated methods into laboratories worldwide, enabling researchers with LC-MS capabilities to generate standardized, reproducible metabolomics data on-site through streamlined workflows, embedded quality controls, automated metabolite annotation, and direct access to Metabolon's Integrated Bioinformatics Platform. Metabolon's industry-leading data, translational science, and bioinformatics expertise help customers and partners resolve some of the most challenging questions in the life sciences, accelerating research and enhancing development success. The company offers scalable, customizable metabolomics and multiomics solutions—from discovery and targeted services to decentralized in-house metabolomics—that support customer needs across academic research, biopharma, core facilities, and CROs, from early discovery through clinical trials and product life-cycle management. For more information, please visit www.metabolon.com and follow us on LinkedIn and X.
Media Inquiries:
Sean Iverson
VP, Global Marketing
siverson@metabolon.com
-
千寻AAA认证宣传内容11.10千寻AAA认证媒体文案11.10 1. 硬核实力体现!千寻获多项“AAA级诚信”认证 当美业赛道轮番更迭营销风口、扩张浪潮此起彼伏,真正能够穿越周期、沉淀为国民2026-11-11
-
银启健康产业集团首展第九届进博会:以自主营养科技链接全球2026年11月10日,上海——11月5日至10日,第九届中国国际进口博览会(以下简称“进博会”)在上海举行。作为世界上第一个以进口为主题的国家级展会,进博会已成为新产品、2026-11-11
-
2027长三角应急展观众预登记正式启动:聚焦AI赋能应急,共探城市韧性未来2027年5月11日至13日,国家会展中心(上海),三展联动,汇聚全球安全应急创新力量 * 观众预登记正式开启,实名登记免费参观; * 规划展览面积60,000平方米,预计汇聚800余家2026-11-11
-
九载赴约结硕果 于平凡处见非凡Brother第九届进博会圆满收官 上海2026年11月11日 美通社 -- 11月10日,第九届中国国际进口博览会在上海国家会展中心圆满落下帷幕。作为连续九年参展的进博会“全2026-11-11
-
阿特拉斯•科普柯与鞍钢集团在第九届进博会签署长期合作协议 共促钢铁行业绿色低碳与智能化发展上海2026年11月11日 美通社 -- 在第九届中国国际进口博览会首日 ,阿特拉斯•科普柯(上海)贸易有限公司与鞍钢集团国际经济贸易有限公司举行长期合作框架协议签约仪式。2026-11-11
-
AMD股价暴跌17%创近9年之最,苏姿丰紧急回应:AI增速远超想象
-
锚定健康中国新征程!第一届医药信息传播论坛将于广州启幕
-
Ledger 中国销售渠道说明:广州馨潇贸易有限公司官方直营渠道公示
-
江苏省脑机接口产业联盟在宁成立,麦澜德分享前沿成果
-
艾芬达入选国家知识产权强国建设示范创建对象:二十载长期主义,兑现每一份用户价值
-
Esentia宣布成功完成2033年到期的6.125%优先票据和2038年到期的6.500%优先票据的定价
-
中荷人寿北京分公司成功举办中荷创享家品牌发布暨协同发展启航仪式
-
华为系具身智能公司具脑磐石完成新一轮融资:对标JEPA,押注类脑智能的认知世界模型
-
北京暑假补习班有哪些?家长首推一对一权威机构金博升学
-
上海高新技术企业代理机构深度访谈与推荐
